Belgium· BE-AMP-SAM590382-00
Voxzogo 0.56 mg
A vosoritide product containing vosoritide, registered in Belgium by BioMarin International. The same ATC class is registered in 10 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Vosoritide is registered in 10 of 19 countries.
Countries holding a registration under ATC M05BX07 (vosoritide), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Vosoritide · ATC M05BX07
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Vosoritide
- Manufacturer
- BioMarin International
- Country
- Belgium (BE)
- ATC code
- M05BX07
- ATC class
- Vosoritide
- Defined daily dose
- 0.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb5878632
- be_apb7750557
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vosoritide in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandVoxzogo 0.56 mg, Pulver und Lösungsmittel zur Herstellung einer InjektionslösungDRAC AG
- SpainVOXZOGO 0,56 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEBiomarin International Limited
- IcelandVoxzogoBioMarin International Limited
- PolandVoxzogoBioMarin International Ltd.
- SwedenVoxzogo 0,56 mg Pulver och vätska till injektionsvätska, lösningBioMarin International Limited
- NetherlandsVoxzogo 0,4 mg, poeder en oplosmiddel voor oplossing voor injectieBioMarin International Limited
- CzechiaVOXZOGOBioMarin International Limited, Dublin
- FinlandVoxzogoBiomarin International Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Voxzogo
- Liechtenstein · Voxzogo
- Norway · Voxzogo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b18f22d8-fe3b-4c5d-92b5-0f92d44f0029 GET /v1/drugs/b18f22d8-fe3b-4c5d-92b5-0f92d44f0029?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Voxzogo 0.56 mg",
"name_fr": "Voxzogo 0.56 mg",
"name_nl": "Voxzogo 0.56 mg",
"amp_code": "SAM590382-00",
"strengths": [
"0.5600"
],
"pack_count": 1,
"substances": [
"Vosoritide",
"Mannitol",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Vosoritide",
"authorisation_numbers": [
"EU/1/21/1577/002"
]
}See everything about vosoritide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.